A Study of the Safety and Efficacy of EBV Specific T-cell Lines
Lymphoma | Epstein-Barr Virus Infections | Post-Transplant Lymphoproliferative DisorderThis study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients suffering from high EBV viral titers not responding to standard of care therapies and to treat EBV-related lymphoma. The study will recruit 6 patients to receive autologous T cells or a T cell line derived from the patient's allogeneic donor (in the case of stem cell transplant recipients), and 6 patients to receive a T-cell line prepared from a matched or partially matched related donor.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
* Capacity to provide informed consent
* Age ≥ 18 years old
* Confirmed treatment-refractory EBV reactivation or EBV-related lymphoma
* ECOG of 2 or less
Exclusion Criteria:
* Medical condition requiring a corticosteroid dose greater than Prednisone 0.5mg/kg/day (or equivalent) at the time of the infusion.
* Patient has received T-cell depleting antibodies or stem cell transplantation in the 28 days prior to proposed date of anti-EBV T-cell line infusion
* Patient has received a solid organ transplant in the 3 months prior to proposed date of anti-EBV T-cell line infusion.
* Pregnant or nursing females
* Life expectancy of less than 3 months due to a condition unrelated to the EBV- related disease.
* Active uncontrolled GVHD
* Active uncontrolled SOT rejection episode
DONOR ELIGIBILITY: An allogeneic donor must be a first-degree relative with at least 3/6 HLA compatibility, have consented to donate peripheral blood mononuclear cells, and fulfill the same criteria for stem cell donation according to the hospital's standard operating procedure.
Study Location
Hôpital Maisonneuve-Rosemont
Hôpital Maisonneuve-RosemontMontreal, Quebec
Canada
Contact Study Team
- Study Sponsored By
- Maisonneuve-Rosemont Hospital
- Participants Required
- More Information
- Study ID:
NCT02580539